| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | Chief Commercial Officer
1 company
Jeffrey Dierks last filed a Form 4 in March 2025, as Chief Commercial Officer at HRMY. Jeffrey Dierks's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Jeffrey Dierks a middling insider score of 62/100, based on 28 past trades. Over a 12-month horizon, 53.6% of those trades were profitable, with an average 12-month return of -1.5%.
Jeffrey Dierks has 28 Form 4 filings on record from August 2020 to March 2025, all as Chief Commercial Officer at Harmony Biosciences (HRMY), 2020–2025.
The 75 reported transactions were 38 open-market sales, 28 option exercises, 7 option or other derivative awards and 2 tax withholdings.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $11.9M.
The largest open-market sale was 35,846 shares of HRMY at an average $40.03 on September 30, 2024, about $1.4M. Twelve months later HRMY was down 31%.
6 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 4,869 | $32.67 | $159,089.50 | - | +10.5% | -12.1% | |
| Jan 27, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 14,754 | $37.38 | $551,575.01 | - | -23.2% | -1.5% | |
| Jan 21, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 30,598 | $37.51 | $1,147,715.34 | - | -29.6% | -9.3% | |
| Jan 15, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 10,507 | $37.01 | $388,840.95 | - | -22.2% | -1.4% | |
| Jan 13, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 7,180 | $37.04 | $265,946.48 | - | -19.0% | -1.9% | |
| Oct 29, 2024 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 21,496 | $40.47 | $870,018.36 | - | -7.8% | -29.3% | |
| Oct 3, 2024 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sell | 36,357 | $35.06 | $1,274,546.50 | -100% | +0.2% | -21.5% | |
| Oct 1, 2024 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE | 400 | $40.19 | $16,076.92 | - | -13.2% | -31.4% | |
| Sep 30, 2024 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE | 35,846 | $40.03 | $1,434,951.23 | - | -14.8% | -31.1% | |
| Sep 27, 2024 | HRMY Harmony Biosciences Holdings, Inc. | Chief Commercial Officer | Sale+OE | 200 | $40.05 | $8,009.00 | - | -11.3% | -29.7% |